Development of new strategy for severe heart failure using aoutologous myoblast sheets.

Development of new strategy for severe heart failure using aoutologous myoblast sheets. - Autologus myoblast sheets transplantation therapy for ischaemic and dilated cardiomyopathy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003273

Enrollment

Registered

2010-03-01

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischaemic cardiomyopathy, dilated cardiomyopathy

Interventions

Culture of autologous skeltal myoblasts and engineering myoblast sheets. Transplantation of the myoblast sheets to the heart.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ischaemic or dilated cardiomyopathy, NYHA Class III and Class IV, Ejection fraction <35%,

Exclusion criteria

Exclusion criteria: Severe skeletal muscle disease, Cancer, Severe infection, Alcoholic or drug addiction in recent six months, Pregnancy, Others (doctors dicision) ,

Design outcomes

Primary

Measure	Time frame
Adverse events	—

Secondary

Measure	Time frame
Caridac function	—

Countries

Japan

Contacts

Public ContactShigeru Miyagawa

Osaka University Graduate school of medicine Cardiovascular surgery

miyagawa@surg1.med.osaka-u.ac.jp06-6879-3154

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026